Regeneron Is Playing Defense With Capital Allocation
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...
Bellevue startup, armed with $320 million, undertakes ambitious project to aid medical research
Regeneron, San Diego-based biotech company Illumina and 17 health systems invested in the $320 million round. Regeneron ...
U.S. News & World Report11d
Regeneron Beats Quarterly Estimates on Eczema Drug Demand; Launches Dividend Program
(Reuters) - Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback ...